Researchers at Integra Therapeutics, in collaboration with Pompeu Fabra University and the Center for Genomic Regulation, have developed synthetic proteins designed through generative AI that outperform naturally occurring proteins in genome editing activity. These novel proteins enhance efficiency and specificity, potentially enabling more precise and effective therapeutic gene editing applications. The study signifies a major advance in protein engineering, demonstrating AI’s capability to surpass evolutionary solutions in biomedical tool development.